Immunotherapy of diffuse gliomas: Biological background, current status and future developments

Brain Pathology

Volumn 19, Issue 4, 2009, Pages 674-693

  Grauer, Oliver M ^b,e   Wesseling, Pieter ^c,d   Adema, Gosse J ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Tumor Immunology ^*  (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

Central nervous system; Dendritic cell; Glioma; Immune escape; Immunotherapy; Vaccine

Indexed keywords

CANCER TESTIS ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DACLIZUMAB; DIFFERENTIATION ANTIGEN; PATTERN RECOGNITION RECEPTOR; RESIQUIMOD; STAT3 PROTEIN; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTIGEN EXPRESSION; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CELL MATURATION; CELL MIGRATION; CELL POLARITY; CELL STIMULATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DENDRITIC CELL; GLIOBLASTOMA; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; MACROPHAGE; MICROGLIA; NONHUMAN; PARENCHYMA; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC PROTOCOLS; BRAIN NEOPLASMS; CANCER VACCINES; CENTRAL NERVOUS SYSTEM; COMBINED MODALITY THERAPY; DENDRITIC CELLS; GLIOMA; HUMANS; IMMUNOTHERAPY;

EID: 69949148057     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2009.00315.x     Document Type: Review

References (302)

1. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ (2008) Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 57 : 1559 1568.
2. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY et al (2008) The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14 : 8228 8235.
3. Adema GJ, Hartgers F, Verstraten R, de Vries E, Marland G, Menon S et al (1997) A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 387 : 713 717.
4. Akasaki Y, Liu G, Chung NH, Ehtesham M, Black KL, Yu JS (2004) Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol 173 : 4352 4359.
5. Albert ML, Sauter B, Bhardwaj N (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 : 86 89.
6. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH (1997) Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 23 : 406 415.
7. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13 : 1050 1059.
8. Apetoh L, Tesniere A, Ghiringhelli F, Kroemer G, Zitvogel L (2008) Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies. Cancer Res 68 : 4026 4030.
9. Asavaroengchai W, Kotera Y, Mule JJ (2002) Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Natl Acad Sci U S A 99 : 931 936.
10. Audia S, Nicolas A, Cathelin D, Larmonier N, Ferrand C, Foucher P et al (2007) Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 150 : 523 530.
11. Babcock AA, Kuziel WA, Rivest S, Owens T (2003) Chemokine expression by glial cells directs leukocytes to sites of axonal injury in the CNS. J Neurosci 23 : 7922 7930.
12. Baccala R, Gonzalez-Quintial R, Dummer W, Theofilopoulos AN (2005) Tumor immunity via homeostatic T cell proliferation: mechanistic aspects and clinical perspectives. Springer Semin Immunopathol 27 : 75 85.
13. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ et al (2000) Immunobiology of dendritic cells. Annu Rev Immunol 18 : 767 811.
14. Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM (2006) Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 108 : 2655 2661.
15. Banissi C, Ghiringhelli F, Chen L, Carpentier AF (2009) Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother Feb 17 [Epub ahead of print] DOI: 10.1007/s00262-009-0671-1.
16. Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH (1989) Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70 : 175 182.
17. Bechmann I (2005) Failed central nervous system regeneration: a downside of fimmune privilege? Neuromolecular Med 7 : 217 228.
18. Bechmann I, Priller J, Kovac A, Bontert M, Wehner T, Klett FF et al (2001) Immune surveillance of mouse brain perivascular spaces by blood-borne macrophages. Eur J Neurosci 14 : 1651 1658.
19. Bechmann I, Galea I, Perry VH (2007) What is the blood-brain barrier (not)? Trends Immunol 28 : 5 11.
20. Behrem S, Zarkovic K, Eskinja N, Jonjic N (2005) Distribution pattern of tenascin-C in glioblastoma: correlation with angiogenesis and tumor cell proliferation. Pathol Oncol Res 11 : 229 235.
21. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ et al (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67 : 4010 4015.
22. Benitez-Ribas D, Adema GJ, Winkels G, Klasen IS, Punt CJ, Figdor CG, de Vries IJ (2006) Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake. J Exp Med 203 : 1629 1635.
23. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 : 235 238.
24. Bettelli E, Korn T, Kuchroo VK (2007) Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 19 : 652 657.
25. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R (2008) Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 38 : 1033 1042.
26. Birnbaum T, Roider J, Schankin CJ, Padovan CS, Schichor C, Goldbrunner R, Straube A (2007) Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J Neurooncol 83 : 241 247.
27. Blancher A, Roubinet F, Grancher AS, Tremoulet M, Bonate A, Delisle MB et al (1993) Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur Cytokine Netw 4 : 331 341.
28. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A (1989) Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol 143 : 3222 3229.
29. Boskovitz A, Wikstrand CJ, Kuan CT, Zalutsky MR, Reardon DA, Bigner DD (2004) Monoclonal antibodies for brain tumour treatment. Expert Opin Biol Ther 4 : 1453 1471.
30. Boullart AC, Aarntzen EH, Verdijk P, Jacobs JF, Schuurhuis DH, Benitez-Ribas D et al (2008) Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E(2) results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 57 : 1589 1597.
31. Bourquin C, Schmidt L, Hornung V, Wurzenberger C, Anz D, Sandholzer N et al (2007) Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response. Blood 109 : 2953 2960.
32. Buccoliero AM, Caldarella A, Gheri CF, Taddei A, Paglierani M, Pepi M et al (2006) Inducible cyclooxygenase (COX-2) in glioblastoma-clinical and immunohistochemical (COX-2-VEGF) correlations. Clin Neuropathol 25 : 59 66.
33. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG (2001) B cells and professional APCs recruit regulatory T cells via CCL4. Nat Immunol 2 : 1126 1132.
34. Calzascia T, Di Berardino-Besson W, Wilmotte R, Masson F, de Tribolet N, Dietrich PY, Walker PR (2003) Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol 171 : 2187 2191.
35. Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, Aurrand-Lions M et al (2005) Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 22 : 175 184.
36. Carpentier A, Laigle-Donadey F, Zohar S, Capelle L, Behin A, Tibi A et al (2006) Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncol 8 : 60 66.
37. Carpentier AF, Chen L, Maltonti F, Delattre JY (1999) Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res 59 : 5429 5432.
38. Carpentier AF, Xie J, Mokhtari K, Delattre JY (2000) Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6 : 2469 2473.
39. Carrithers MD, Visintin I, Kang SJ, Janeway CA, Jr. (2000) Differential adhesion molecule requirements for immune surveillance and inflammatory recruitment. Brain 123 : 1092 1101.
40. Carson KA, Grossman SA, Fisher JD, Shaw EG (2007) Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 25 : 2601 2606.
41. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC (2006) CNS immune privilege: hiding in plain sight. Immunol Rev 213 : 48 65.
42. Castelli MG, Chiabrando C, Fanelli R, Martelli L, Butti G, Gaetani P, Paoletti P (1989) Prostaglandin and thromboxane synthesis by human intracranial tumors. Cancer Res 49 : 1505 1508.
43. Cayrol R, Wosik K, Berard JL, Dodelet-Devillers A, Ifergan I, Kebir H et al (2008) Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol 9 : 137 145.
44. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N et al (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198 : 1875 1886.
45. Chi DD, Merchant RE, Rand R, Conrad AJ, Garrison D, Turner R et al (1997) Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. AmJPathol 150 : 2143 2152.
46. Choi BD, Archer GE, Mitchell DA, Heimberger AB, McLendon RE, Bigner DD, Sampson JH (2009) EGFRvIII-targeted peptide vaccine therapy in patients with malignant glioma. Brain Pathol 19 : 713 723.
47. Choi BK, Bae JS, Choi EM, Kang WJ, Sakaguchi S, Vinay DS, Kwon BS (2004) 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol 75 : 785 791.
48. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA (1995) Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res 55 : 727 730.
49. Cross AH, Dolich S, Raine CS (1990) Antigen processing of myelin basic protein is required prior to recognition by T cells inducing EAE. Cell Immunol 129 : 22 31.
50. Cserr HF, DePasquale M, Harling-Berg CJ, Park JT, Knopf PM (1992) Afferent and efferent arms of the humoral immune response to CSF-administered albumins in a rat model with normal blood-brain barrier permeability. J Neuroimmunol 41 : 195 202.
51. Curtin JF, Candolfi M, Fakhouri TM, Liu C, Alden A, Edwards M et al (2008) Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS ONE 3 : e1983.
52. Curtin JF, Liu N, Candolfi M, Xiong W, Assi H, Yagiz K et al (2009) HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 6 : e10.
53. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D et al (2005) Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 115 : 3623 3633.
54. De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J et al (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14 : 3098 3104.
55. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ et al (2003) Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 9 : 5091 5100.
56. Desbaillets I, Tada M, de Tribolet N, Diserens AC, Hamou MF, Van Meir EG (1994) Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and in vitro. Int J Cancer 58 : 240 247.
57. Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG (1997) Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J Exp Med 186 : 1201 1212.
58. Deshpande P, King IL, Segal BM (2007) Cutting edge: CNS CD11c+ cells from mice with encephalomyelitis polarize Th17 cells and support CD25+CD4+ T cell-mediated immunosuppression, suggesting dual roles in the disease process. J Immunol 178 : 6695 6699.
59. Dillman RO, Duma CM, Schiltz PM, DePriest C, Ellis RA, Okamoto K et al (2004) Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27 : 398 404.
60. Dix AR, Brooks WH, Roszman TL, Morford LA (1999) Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 100 : 216 232.
61. Dunn GP, Dunn IF, Curry WT (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 7 : 12.
62. El Andaloussi A, Lesniak MS (2006) An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro-oncol 8 : 234 243.
63. Engelhardt B, Wolburg H (2004) Mini-review: transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol 34 : 2955 2963.
64. Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M et al (2005) Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res 11 : 8304 8311.
65. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 172 : 5149 5153.
66. Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, Archer GE et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66 : 3294 3302.
67. Fecci PE, Ochiai H, Mitchell DA, Grossi PM, Sweeney AE, Archer GE et al (2007) Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 13 : 2158 2167.
68. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M et al (1999) Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5 : 405 411.
69. Fischer HG, Bonifas U, Reichmann G (2000) Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with Toxoplasma gondii. J Immunol 164 : 4826 4834.
70. Fischer HG, Reichmann G (2001) Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol 166 : 2717 2726.
71. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4 : 330 336.
72. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM (2003) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J Exp Med 198 : 267 279.
73. Fujita M, Zhu X, Ueda R, Sasaki K, Kohanbash G, Kastenhuber ER et al (2009) Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res 69 : 1587 1595.
74. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H et al (2003) CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 63 : 8302 8311.
75. Galea I, Bernardes-Silva M, Forse PA, van Rooijen N, Liblau RS, Perry VH (2007) An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J Exp Med 204 : 2023 2030.
76. Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C et al (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34 : 336 344.
77. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N et al (2005) CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 202 : 1075 1085.
78. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F et al (2007) Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 56 : 641 648.
79. Gilboa E (2007) DC-based cancer vaccines. J Clin Invest 117 : 1195 1203.
80. Gordon LB, Knopf PM, Cserr HF (1992) Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites. J Neuroimmunol 40 : 81 87.
81. Gorelik L, Constant S, Flavell RA (2002) Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J Exp Med 195 : 1499 1505.
82. Graf MR, Sauer JT, Merchant RE (2005) Tumor infiltration by myeloid suppressor cells in response to T cell activation in rat gliomas. J Neurooncol 73 : 29 36.
83. Grant RS, Naif H, Espinosa M, Kapoor V (2000) IDO induction in IFN-gamma activated astroglia: a role in improving cell viability during oxidative stress. Redox Rep 5 : 101 104.
84. Grauer O, Poschl P, Lohmeier A, Adema GJ, Bogdahn U (2007) Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. J Neurooncol 82 : 151 161.
85. Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, Wesseling P et al (2007) CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 121 : 95 105.
86. Grauer OM, Molling JW, Bennink E, Toonen LW, Sutmuller RP, Nierkens S, Adema GJ (2008) TLR ligands in the local treatment of established intracerebral murine gliomas. J Immunol 181 : 6720 6729.
87. Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, Toonen LW et al (2008) Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 122 : 1794 1802.
88. Grayson G, Ladisch S (1992) Immunosuppression by human gangliosides. II. Carbohydrate structure and inhibition of human NK activity. Cell Immunol 139 : 18 29.
89. Green EA, Choi Y, Flavell RA (2002) Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 16 : 183 191.
90. Greter M, Heppner FL, Lemos MP, Odermatt BM, Goebels N, Laufer T et al (2005) Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11 : 328 334.
91. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ (1997) The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med 185 : 1101 1111.
92. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R et al (2008) Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 27 : 2897 2909.
93. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S et al (2005) Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 11 : 8055 8062.
94. Harling-Berg CJ, Knopf PM, Cserr HF (1991) Myelin basic protein infused into cerebrospinal fluid suppresses experimental autoimmune encephalomyelitis. J Neuroimmunol 35 : 45 51.
95. Harling-Berg CJ, Park TJ, Knopf PM (1999) Role of the cervical lymphatics in the Th2-type hierarchy of CNS immune regulation. J Neuroimmunol 101 : 111 127.
96. Hatterer E, Davoust N, Didier-Bazes M, Vuaillat C, Malcus C, Belin MF, Nataf S (2006) How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 107 : 806 812.
97. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A et al (2007) Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 17 : 201 212.
98. Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ et al (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76 : 840 852.
99. Heckelsmiller K, Beck S, Rall K, Sipos B, Schlamp A, Tuma E et al (2002) Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 32 : 3235 3245.
100. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 : 997 1003.
101. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, Aldape K et al (2008) Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 10 : 98 103.
102. Hickey WF, Hsu BL, Kimura H (1991) T-lymphocyte entry into the central nervous system. J Neurosci Res 28 : 254 260.
103. Hochmeister S, Zeitelhofer M, Bauer J, Nicolussi EM, Fischer MT, Heinke B et al (2008) After injection into the striatum, in vitro-differentiated microglia- and bone marrow-derived dendritic cells can leave the central nervous system via the blood stream. Am J Pathol 173 : 1669 1681.
104. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N et al (2008) CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 5 : 557 561.
105. Hori S, Takahashi T, Sakaguchi S (2003) Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 81 : 331 371.
106. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M et al (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 67 : 792 801.
107. Hu HM, Poehlein CH, Urba WJ, Fox BA (2002) Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 62 : 3914 3919.
108. Huehn J, Siegmund K, Hamann A (2005) Migration rules: functional properties of naive and effector/memory-like regulatory T cell subsets. Curr Top Microbiol Immunol 293 : 89 114.
109. Husain SR, Puri RK (2003) Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 65 : 37 48.
110. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB (2006) The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-oncol 8 : 261 279.
111. Hussain SF, Yang D, Suki D, Grimm E, Heimberger AB (2006) Innate immune functions of microglia isolated from human glioma patients. J Transl Med 4 : 15.
112. Hussain SF, Kong LY, Jordan J, Conrad C, Madden T, Fokt I et al (2007) A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 67 : 9630 9636.
113. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, D'Ambrosio D (2001) Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 194 : 847 853.
114. Imaizumi T, Kuramoto T, Matsunaga K, Shichijo S, Yutani S, Shigemori M et al (1999) Expression of the tumor-rejection antigen SART1 in brain tumors. Int J Cancer 83 : 760 764.
115. Ingram M, Buckwalter JG, Jacques DB, Freshwater DB, Abts RM, Techy GB et al (1990) Immunotherapy for recurrent malignant glioma: an interim report on survival. Neurol Res 12 : 265 273.
116. Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M (2002) A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22 (2A 613 621.
117. Ishii KJ, Coban C, Akira S (2005) Manifold mechanisms of toll-like receptor-ligand recognition. J Clin Immunol 25 : 511 521.
118. Ishii N, Tada M, Sakuma S, Sawamura Y, Shinohe Y, Abe H (1998) Human astrocytoma cells are capable of producing macrophage inflammatory protein-1beta. J Neurooncol 37 : 17 23.
119. Itano AA, McSorley SJ, Reinhardt RL, Ehst BD, Ingulli E, Rudensky AY, Jenkins MK (2003) Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19 : 47 57.
120. Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I et al (2007) A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene 26 : 2435 2444.
121. Iwasaki A, Medzhitov R (2004) Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 : 987 995.
122. Jachimczak P, Bogdahn U, Schneider J, Behl C, Meixensberger J, Apfel R et al (1993) The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J Neurosurg 78 : 944 951.
123. Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH et al (1996) Transforming growth factor-beta-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65 : 332 337.
124. Jacobs JF, Grauer OM, Brasseur F, Hoogerbrugge PM, Wesseling P, Gidding CE et al (2008) Selective cancer-germline gene expression in pediatric brain tumors. J Neurooncol 88 : 273 280.
125. Jacobs JF, Idema AJ, Bol K, Nierkens S, Grauer OM, Wesseling P et al (2008) Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-Oncology Nov 21 [Epub ahead of print] DOI: 10.1215/15228517-2008-104.
126. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA (1986) Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res 46 : 2101 2104.
127. Jameson SC (2002) Maintaining the norm: T-cell homeostasis. Nat Rev Immunol 2 : 547 556.
128. Janeway CA, Jr., Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20 : 197 216.
129. Jeffes EW, 3rd., Beamer YB, Jacques S, Silberman RS, Vayuvegula B, Gupta S et al (1993) Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA. J Neurooncol 15 : 141 155.
130. Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH (2000) Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 192 : 1213 1222.
131. Jordan JT, Sun W, Hussain SF, Deangulo G, Prabhu SS, Heimberger AB (2008) Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 57 : 123 131.
132. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T et al (2002) In vivo depletion of CD11c(+) dendritic cells abrogates priming of CD8(+) T cells by exogenous cell-associated antigens. Immunity 17 : 211 220.
133. Kajiwara Y, Yamasaki F, Hama S, Yahara K, Yoshioka H, Sugiyama K et al (2003) Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis. Cancer 97 : 1077 1083.
134. Kalinski P, Schuitemaker JH, Hilkens CM, Wierenga EA, Kapsenberg ML (1999) Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 162 : 3231 3236.
135. Karman J, Ling C, Sandor M, Fabry Z (2004) Initiation of immune responses in brain is promoted by local dendritic cells. J Immunol 173 : 2353 2361.
136. Karman J, Chu HH, Co DO, Seroogy CM, Sandor M, Fabry Z (2006) Dendritic cells amplify T cell-mediated immune responses in the central nervous system. J Immunol 177 : 7750 7760.
137. Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL et al (2004) Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 27 : 452 459.
138. Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S (2001) Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Cancer Res 61 : 2031 2037.
139. Kitahara T, Watanabe O, Yamaura A, Makino H, Watanabe T, Suzuki G, Okumura K (1987) Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor. J Neurooncol 4 : 329 336.
140. Kjaergaard J, Wang LX, Kuriyama H, Shu S, Plautz GE (2005) Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 103 : 156 164.
141. Kjellman C, Olofsson SP, Hansson O, Von Schantz T, Lindvall M, Nilsson I et al (2000) Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer 89 : 251 258.
142. Konnikova L, Kotecki M, Kruger MM, Cochran BH (2003) Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer 3 : 23.
143. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB et al (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448 : 484 487.
144. Korn T, Reddy J, Gao W, Bettelli E, Awasthi A, Petersen TR et al (2007) Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 13 : 423 431.
145. Kreijveld E, Koenen HJ, Klasen IS, Hilbrands LB, Joosten I (2007) Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 7 : 249 255.
146. Kreitman RJ (2004) Recombinant immunotoxins for the treatment of haematological malignancies. Expert Opin Biol Ther 4 : 1115 1128.
147. Kruse CA, Cepeda L, Owens B, Johnson SD, Stears J, Lillehei KO (1997) Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother 45 : 77 87.
148. Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, Zou W (2007) Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol 179 : 1423 1426.
149. Kumar H, Kawai T, Akira S (2009) Pathogen recognition in the innate immune response. Biochem J 420 : 1 16.
150. Kunwar S (2003) Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 88 : 105 111.
151. Kuramoto T (1997) Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med J 44 : 43 51.
152. Kuwashima N, Nishimura F, Eguchi J, Sato H, Hatano M, Tsugawa T et al (2005) Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 175 : 2730 2740.
153. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 5 : 397 405.
154. Lee HK, Iwasaki A (2007) Innate control of adaptive immunity: dendritic cells and beyond. Semin Immunol 19 : 48 55.
155. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9 : 391 403.
156. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11 : 5515 5525.
157. Ling C, Sandor M, Fabry Z (2003) In situ processing and distribution of intracerebrally injected OVA in the CNS. J Neuroimmunol 141 : 90 98.
158. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS (2004) HER-2, gp100,
159. Liu K, Iyoda T, Saternus M, Kimura Y, Inaba K, Steinman RM (2002) Immune tolerance after delivery of dying cells to dendritic cells in situ. J Exp Med 196 : 1091 1097.
160. Liu K, Idoyaga J, Charalambous A, Fujii S, Bonito A, Mordoh J et al (2005) Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells. J Exp Med 202 : 1507 1516.
161. Liu Y, Wang Q, Kleinschmidt-DeMasters BK, Franzusoff A, Ng KY, Lillehei KO (2007) TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors. J Neurooncol 81 : 149 162.
162. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 114 : 97 109.
163. Mackall CL, Bare CV, Granger LA, Sharrow SO, Titus JA, Gress RE (1996) Thymic-independent T cell regeneration occurs via antigen-driven expansion of peripheral T cells resulting in a repertoire that is limited in diversity and prone to skewing. J Immunol 156 : 4609 4616.
164. Maes W, Rosas GG, Verbinnen B, Boon L, De Vleeschouwer S, Ceuppens JL, Van Gool SW (2009) DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol March 31 [Epub ahead of print] DOI: 10.1215/15228517-2009-004.
165. Mahnke K, Schonfeld K, Fondel S, Ring S, Karakhanova S, Wiedemeyer K et al (2007) Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int J Cancer 120 : 2723 2733.
166. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML et al (2004) alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 64 : 5934 5937.
167. MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A, Sallusto F (2003) Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 198 : 615 621.
168. Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR (2007) Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol 179 : 845 853.
169. Matyszak MK, Perry VH (1996) The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system. Neuroscience 74 : 599 608.
170. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC (2002) CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16 : 311 323.
171. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD (2005) Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11 : 335 339.
172. McMahon EJ, Bailey SL, Miller SD (2006) CNS dendritic cells: critical participants in CNS inflammation? Neurochem Int 49 : 195 203.
173. Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H (2007) WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol 114 : 111 119.
174. Meng Y, Carpentier AF, Chen L, Boisserie G, Simon JM, Mazeron JJ, Delattre JY (2005) Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer 116 : 992 997.
175. Miller SD, McMahon EJ, Schreiner B, Bailey SL (2007) Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 1103 : 179 191.
176. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 10 : 10 18.
177. Miyazaki T, Moritake K, Yamada K, Hara N, Osago H, Shibata T et al (2009) Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. J Neurosurg Jan 23 [Epub ahead of print] DOI: 10.3171/2008.10.JNS081141.
178. Mottet C, Golshayan D (2007) CD4+CD25+Foxp3+ regulatory T cells: from basic research to potential therapeutic use. Swiss Med Wkly 137 : 625 634.
179. Munn DH, Sharma MD, Lee JR, Jhaver KG, Johnson TS, Keskin DB et al (2002) Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297 : 1867 1870.
180. Murayama K, Kobayashi T, Imaizumi T, Matsunaga K, Kuramoto T, Shigemori M et al (2000) Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 23 : 511 518.
181. Nair S, McLaughlin C, Weizer A, Su Z, Boczkowski D, Dannull J et al (2003) Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J Immunol 171 : 6275 6282.
182. Nam DH, Park K, Park C, Im YH, Kim MH, Lee S et al (2004) Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep 11 : 263 268.
183. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6 : 769 776.
184. Newcomb EW, Demaria S, Lukyanov Y, Shao Y, Schnee T, Kawashima N et al (2006) The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clin Cancer Res 12 : 4730 4737.
185. Nitta T, Hishii M, Sato K, Okumura K (1994) Selective expression of interleukin-10 gene within glioblastoma multiforme. Brain Res 649 : 122 128.
186. Njoku C, Self SE, Ruiz P, Hofbauer AF, Gilkeson GS, Oates JC (2008) Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in mrl/lpr mice deficient in the nos2 gene. J Investig Med 56 : 911 919.
187. Nonaka Y, Tsuda N, Shichijo S, Ito M, Maeda Y, Harada M et al (2002) Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes from patients with brain tumors. Tissue Antigens 60 : 319 327.
188. North RJ (1984) Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother 16 : 175 181.
189. Nummer D, Suri-Payer E, Schmitz-Winnenthal H, Bonertz A, Galindo L, Antolovich D et al (2007) Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst 99 : 1188 1199.
190. O'Connor RA, Malpass KH, Anderton SM (2007) The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells. J Immunol 179 : 958 966.
191. O'Garra A (1998) Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 8 : 275 283.
192. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al (2007) Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13 : 54 61. (Pubitemid 46067386)
193. Okada H, Lieberman FS, Edington HD, Witham TF, Wargo MJ, Cai Q et al (2003) Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol 64 : 13 20.
194. Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K et al (2004) Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res 64 : 5830 5838.
195. Olson JK, Miller SD (2004) Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173 : 3916 3924.
196. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M et al (2008) Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14 : 8205 8212.
197. Pashenkov M, Huang YM, Kostulas V, Haglund M, Soderstrom M, Link H (2001) Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain 124 : 480 492.
198. Pashenkov M, Teleshova N, Link H (2003) Inflammation in the central nervous system: the role for dendritic cells. Brain Pathol 13 : 23 33.
199. Perrin G, Schnuriger V, Quiquerez AL, Saas P, Pannetier C, de Tribolet N et al (1999) Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. Int Immunol 11 : 1337 1350.
200. Plautz GE, Miller DW, Barnett GH, Stevens GH, Maffett S, Kim J et al (2000) T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 6 : 2209 2218.
201. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS et al (2008) 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 14 : 1256 1263.
202. Powell DJ, Jr., Felipe-Silva A, Merino MJ, Ahmadzadeh M, Allen T, Levy C et al (2007) Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol 179 : 4919 4928.
203. Prins RM, Scott GP, Merchant RE, Graf MR (2002) Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression. Cancer Immunol Immunother 51 : 190 199.
204. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R et al (2006) The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 176 : 157 164.
205. Prins RM, Shu CJ, Radu CG, Vo DD, Khan-Farooqi H, Soto H et al (2008) Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain. Cancer Immunol Immunother 57 : 1279 1289.
206. Quattrocchi KB, Miller CH, Cush S, Bernard SA, Dull ST, Smith M et al (1999) Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. J Neurooncol 45 : 141 157.
207. Rahaman SO, Vogelbaum MA, Haque SJ (2005) Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: involvement of IL-13Ralpha2. Cancer Res 65 : 2956 2963.
208. Ransohoff RM, Kivisakk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3 : 569 581.
209. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L et al (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 11 : 1230 1237.
210. Recht L, Torres CO, Smith TW, Raso V, Griffin TW (1990) Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapy. J Neurosurg 72 : 941 945.
211. Redjal N, Chan JA, Segal RA, Kung AL (2006) CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 12 : 6765 6771.
212. Reis e Sousa C (2004) Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol 16 : 27 34.
213. Reis e Sousa C, Yap G, Schulz O, Rogers N, Schito M, Aliberti J et al (1999) Paralysis of dendritic cell IL-12 production by microbial products prevents infection-induced immunopathology. Immunity 11 : 637 647.
214. Rodriguez PC, Quiceno DG, Zabaleta J, Ortiz B, Zea AH, Piazuelo MB et al (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res 64 : 5839 5849.
215. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB et al (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202 : 931 939.
216. Roggendorf W, Strupp S, Paulus W (1996) Distribution and characterization of microglia/macrophages in human brain tumors. Acta Neuropathol 92 : 288 293.
217. Rossi ML, Hughes JT, Esiri MM, Coakham HB, Brownell DB (1987) Immunohistological study of mononuclear cell infiltrate in malignant gliomas. Acta Neuropathol 74 : 269 277.
218. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A et al (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5 : 241 251.
219. Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kuhl J, Demaerel P et al (2004) Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91 : 1656 1662.
220. Safdari H, Hochberg FH, Richardson EP, Jr. (1979) Histological correlations with survival in malignant gliomas. Acta Neurochir Suppl (Wien) 28 : 485 488.
221. Safdari H, Hochberg FH, Richardson EP, Jr. (1985) Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas. Surg Neurol 23 : 221 226.
222. Sahin U, Koslowski M, Tureci O, Eberle T, Zwick C, Romeike B et al (2000) Expression of cancer testis genes in human brain tumors. ClinCancer Res 6 : 3916 3922.
223. Sakaguchi S (2004) Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22 : 531 562. (Pubitemid 38680433)
224. Sakaguchi S (2005) Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 6 : 345 352.
225. Sakaguchi S (2008) Regulatory T cells in the past and for the future. Eur J Immunol 38 : 901 937.
226. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD (2008) Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20 : 267 275.
227. Santambrogio L, Belyanskaya SL, Fischer FR, Cipriani B, Brosnan CF, Ricciardi-Castagnoli P et al (2001) Developmental plasticity of CNS microglia. Proc Natl Acad Sci U S A 98 : 6295 6300.
228. Sasaki A, Nakazato Y, Ogawa A, Sugihara S (1996) The immunophenotype of perivascular cells in the human brain. Pathol Int 46 : 15 23.
229. Sasaki M, Nakahira K, Kawano Y, Katakura H, Yoshimine T, Shimizu K et al (2001) MAGE-E1, a new member of the melanoma-associated antigen gene family and its expression in human glioma. Cancer Res 61 : 4809 4814.
230. Scarcella DL, Chow CW, Gonzales MF, Economou C, Brasseur F, Ashley DM (1999) Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 5 : 335 341.
231. Scheel B, Aulwurm S, Probst J, Stitz L, Hoerr I, Rammensee HG et al (2006) Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur J Immunol 36 : 2807 2816.
232. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P (2006) Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev 17 : 129 139.
233. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 : 480 483.
234. Schonthal AH (2006) Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus 20 : E21.
235. Serafini B, Columba-Cabezas S, Di Rosa F, Aloisi F (2000) Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol 157 : 1991 2002.
236. Serot JM, Bene MC, Foliguet B, Faure GC (2000) Monocyte-derived IL-10-secreting dendritic cells in choroid plexus epithelium. J Neuroimmunol 105 : 115 119.
237. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 3 : 135 142.
238. Shortman K, Naik SH (2007) Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol 7 : 19 30.
239. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM, Jr. (2001) Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res 61 : 363 369.
240. Siegmund K, Feuerer M, Siewert C, Ghani S, Haubold U, Dankof A et al (2005) Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. Blood 106 : 3097 3104.
241. Sombroek CC, Stam AG, Masterson AJ, Lougheed SM, Schakel MJ, Meijer CJ et al (2002) Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol 168 : 4333 4343.
242. Soumelis V, Liu YJ (2006) From plasmacytoid to dendritic cell: morphological and functional switches during plasmacytoid pre-dendritic cell differentiation. Eur J Immunol 36 : 2286 2292.
243. Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG et al (2009) Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 15 : 1086 1095.
244. Sporri R, Reis e Sousa C (2005) Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol 6 : 163 170.
245. Steiner HH, Bonsanto MM, Beckhove P, Brysch M, Geletneky K, Ahmadi R et al (2004) Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 22 : 4272 4281.
246. Steinman RM (2006) Linking innate to adaptive immunity through dendritic cells. Novartis Found Symp 279 : 101 109. discussion 9-13, 216-9.
247. Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K et al (2003) Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 987 : 15 25.
248. Stevenson PG, Hawke S, Sloan DJ, Bangham CR (1997) The immunogenicity of intracerebral virus infection depends on anatomical site. J Virol 71 : 145 151.
249. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987 996.
250. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10 : 459 466.
251. Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C et al (2004) Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 22 : 610 616.
252. Tabatabai G, Bahr O, Mohle R, Eyupoglu IY, Boehmler AM, Wischhusen J et al (2005) Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. Brain 128 : 2200 2211.
253. Tabatabai G, Frank B, Mohle R, Weller M, Wick W (2006) Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. Brain 129 : 2426 2435.
254. Takeda K, Kaisho T, Akira S (2003) Toll-like receptors. Annu Rev Immunol 21 : 335 376.
255. Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S et al (2007) Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol 9 : 259 270.
256. Trinchieri G (1993) Interleukin-12 and its role in the generation of TH1 cells. Immunol Today 14 : 335 338.
257. Tsuda N, Nonaka Y, Shichijo S, Yamada A, Ito M, Maeda Y et al (2002) UDP-Gal: betaGlcNAc beta1, 3-galactosyltransferase, polypeptide 3 (GALT3) is a tumour antigen recognised by HLA-A2-restricted cytotoxic T lymphocytes from patients with brain tumour. Br J Cancer 87 : 1006 1012.
258. Tsugawa T, Kuwashima N, Sato H, Fellows-Mayle WK, Dusak JE, Okada K et al (2004) Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther 11 : 1551 1558.
259. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K et al (2007) Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 56 : 1513 1537.
260. Uccelli A, Pistoia V, Moretta L (2007) Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 28 : 219 226.
261. Ueda R, Iizuka Y, Yoshida K, Kawase T, Kawakami Y, Toda M (2004) Identification of a human glioma antigen, SOX6, recognized by patients' sera. Oncogene 23 : 1420 1427.
262. Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R et al (2004) SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 64 : 7954 7961.
263. Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K et al (2008) Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J Leukoc Biol 83 : 1136 1144.
264. Vajkoczy P, Laschinger M, Engelhardt B (2001) Alpha4-integrin-VCAM-1 binding mediates G protein-independent capture of encephalitogenic T cell blasts to CNS white matter microvessels. J Clin Invest 108 : 557 565.
265. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg AD, Colombo MP (2005) Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105 : 2845 2851.
266. van der Most RG, Currie A, Robinson BW, Lake RA (2006) Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res 66 : 601 604.
267. Van Gool SW, Maes M, Ardon H, Verschuere T, De Vleeschouwer S (2009) Dendritic cell therapy of gliomas. Brain Pathol 19 : 694 712.
268. van Kooyk Y (2008) C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem Soc Trans 36 : 1478 1481.
269. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F et al (2002) Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 196 : 541 549.
270. Villadangos JA, Schnorrer P (2007) Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat Rev Immunol 7 : 543 555.
271. Vlad G, Ho EK, Vasilescu ER, Fan J, Liu Z, Cai JW et al (2007) Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol 18 : 13 21.
272. von Hanwehr RI, Hofman FM, Taylor CR, Apuzzo ML (1984) Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies. J Neurosurg 60 : 1138 1147.
273. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H (2003) Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 18 : 605 617.
274. Walker PR, Calzascia T, Dietrich PY (2002) All in the head: obstacles for immune rejection of brain tumours. Immunology 107 : 28 38.
275. Walker PR, Calzascia T, de Tribolet N, Dietrich PY (2003) T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev 42 : 97 122.
276. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B et al (2006) Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 108 : 544 550.
277. Weaver M, Laske DW (2003) Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 65 : 3 13.
278. Wei J, Duramad O, Perng OA, Reiner SL, Liu YJ, Qin FX (2007) Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 104 : 18169 18174.
279. Wekerle H (1993) T-cell autoimmunity in the central nervous system. Intervirology 35 : 95 100.
280. Wekerle H (2006) Breaking ignorance: the case of the brain. Curr Top Microbiol Immunol 305 : 25 50.
281. Wekerle H, Lassmann H, Linington C, Meyermann R (1986) Cellular immune reactivity within the CNS. Trends Neurosci 9 : 271 277.
282. Weller RO, Djuanda E, Yow HY, Carare RO (2009) Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 117 : 1 14.
283. Wenkel H, Streilein JW, Young MJ (2000) Systemic immune deviation in the brain that does not depend on the integrity of the blood-brain barrier. J Immunol 164 : 5125 5131.
284. Wheeler CJ, Das A, Liu G, Yu JS, Black KL (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10 : 5316 5326.
285. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S et al (2008) Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 68 : 5955 5964.
286. Wiendl H, Mitsdoerffer M, Hofmeister V, Wischhusen J, Bornemann A, Meyermann R et al (2002) A functional role of HLA-G expression in human gliomas: an alternative strategy of immune escape. J Immunol 168 : 4772 4780.
287. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD (1998) The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 4 : 148 158.
288. Wilmotte R, Burkhardt K, Kindler V, Belkouch MC, Dussex G, Tribolet N et al (2005) B7-homolog 1 expression by human glioma: a new mechanism of immune evasion. Neuroreport 16 : 1081 1085.
289. Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R et al (2003) Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res 63 : 7462 7467.
290. Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M (2005) HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol 64 : 523 528.
291. Wood GW, Holladay FP, Turner T, Wang YY, Chiga M (2000) A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. J Neurooncol 48 : 113 120.
292. Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T et al (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89 : 1172 1179.
293. Yamanaka R, Tsuchiya N, Yajima N, Honma J, Hasegawa H, Tanaka R et al (2003) Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg 99 : 746 753.
294. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T et al (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11 : 4160 4167.
295. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM (2003) Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 198 : 235 247.
296. Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, Lee PK et al (2001) Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 61 : 842 847.
297. Yu JS, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64 : 4973 4979.
298. Yu P, Rowley DA, Fu YX, Schreiber H (2006) The role of stroma in immune recognition and destruction of well-established solid tumors. Curr Opin Immunol 18 : 226 231.
299. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N et al (2008) Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 14 : 123 129.
300. Zhang L, Alizadeh D, Van Handel M, Kortylewski M, Yu H, Badie B (2009) Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia March 20 [Epub ahead of print] DOI: 10.1002/glia.20863.
301. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8 : 59 73.
302. Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, Schendel DJ (2007) Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 5 : 18.